Finance

Lists
CRVS:NASDAQ
Corvus Pharmaceuticals Inc
9,38 USD
-0,32%
(-0,030) 1D
9,40 USD
+0,21% (+0,020)
Pre-market
Closed: 14-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRVS...
Open
9,31 USD
High
9,50 USD
Low
9,21 USD
Mkt. cap
789,05 млн
Avg. vol.
1,20 млн
Volume
771,00
52-wk high
26,95 USD
52-wk low
6,39 USD
EPS
-0,62 USD
Beta
1,44
Shares outstanding
84,12 млн
No. of employees
37
Open
9,31 USD
High
9,50 USD
Low
9,21 USD
Mkt. cap
789,05 млн
Avg. vol.
1,20 млн
Volume
771,00
52-wk high
26,95 USD
52-wk low
6,39 USD
EPS
-0,62 USD
Beta
1,44
Shares outstanding
84,12 млн
No. of employees
37
News stories
From web sources and news partners
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersБерлингейм, Калифорния, Америка Кошмо Штаттары
Sector-
Websitecorvuspharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to CRVS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CRVS in the last 3 months.
Highest
Current 9,38 USD
33,00 USD (+251,81%)
Average
29,50 USD (+214,50%)
Lowest
27,00 USD (+187,85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
30,00 USD
+219,8%
08/11/2026
Sean Lee CFA
H.C. Wainwright
Buy
Maintained
27,00 USD
+187,8%
08/10/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
33,00 USD
+251,8%
08/07/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
33,00 USD
+251,8%
08/07/2026
Etzer Darout
Barclays
Buy
Maintained
28,00 USD
+198,5%
08/07/2026
Paul Choi
Goldman Sachs
Buy
Maintained
40,00 USD
+326,4%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8,45 млн
9,94 млн
11,18 млн
15,96 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,12 млн
2,28 млн
3,70 млн
3,33 млн
Operating expense
10,57 млн
12,22 млн
14,88 млн
19,30 млн
Total operating expenses
10,57 млн
12,22 млн
14,88 млн
19,30 млн
Operating income
-10,57 млн
-12,22 млн
-14,88 млн
-19,30 млн
Other non operating income
-
-
-
-
EBT including unusual items
-10,16 млн
-12,32 млн
-13,69 млн
-17,96 млн
EBT excluding unusual items
-10,16 млн
-12,32 млн
-13,69 млн
-17,96 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10,16 млн
-12,32 млн
-13,69 млн
-17,96 млн
Net profit margin
-
-
-
-
Earnings per share
-0,12
-0,15
-0,15
-0,19
Interest and investment income
738,00 миң
603,00 миң
1,78 млн
2,05 млн
Interest expense
-
-
-
-
Net interest expenses
738,00 миң
603,00 миң
1,78 млн
2,05 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,54 млн
-12,19 млн
-14,85 млн
-19,26 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору